<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="cam470655" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Med</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Med</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2045-7634</journal-id><journal-id journal-id-type="publisher-id">CAM4</journal-id><journal-title-group><journal-title>Cancer Medicine</journal-title></journal-title-group><issn pub-type="epub">2045-7634</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40007213</article-id><article-id pub-id-type="pmc">PMC11861570</article-id><article-id pub-id-type="doi">10.1002/cam4.70655</article-id><article-id pub-id-type="publisher-id">CAM470655</article-id><article-id pub-id-type="other">CAM4-2024-04-2365.R3</article-id><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Doxorubicin Plus Dacarbazine Versus Doxorubicin Plus Ifosfamide in Combination With Regional Hyperthermia in Patients With Advanced Leiomyosarcoma: A Propensity Score&#x02010;Matched Analysis</article-title></title-group><contrib-group><contrib id="cam470655-cr-0001" contrib-type="author" corresp="yes"><name><surname>Berclaz</surname><given-names>Luc M.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4405-138X</contrib-id><xref rid="cam470655-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cam470655-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>luc.berclaz@med.uni-muenchen.de</email></address></contrib><contrib id="cam470655-cr-0002" contrib-type="author"><name><surname>Jurinovic</surname><given-names>Vindi</given-names></name><xref rid="cam470655-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cam470655-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="cam470655-cr-0003" contrib-type="author"><name><surname>Burkhard&#x02010;Meier</surname><given-names>Anton</given-names></name><xref rid="cam470655-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cam470655-cr-0004" contrib-type="author"><name><surname>Abdel&#x02010;Rahman</surname><given-names>Sultan</given-names></name><xref rid="cam470655-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cam470655-cr-0005" contrib-type="author"><name><surname>Albertsmeier</surname><given-names>Markus</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5028-5062</contrib-id><xref rid="cam470655-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="cam470655-cr-0006" contrib-type="author"><name><surname>Klein</surname><given-names>Alexander</given-names></name><xref rid="cam470655-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="cam470655-cr-0007" contrib-type="author"><name><surname>D&#x000fc;rr</surname><given-names>Hans Roland</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1347-1173</contrib-id><xref rid="cam470655-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="cam470655-cr-0008" contrib-type="author"><name><surname>Schmidt&#x02010;Hegemann</surname><given-names>Nina&#x02010;Sophie</given-names></name><xref rid="cam470655-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="cam470655-cr-0009" contrib-type="author"><name><surname>Kn&#x000f6;sel</surname><given-names>Thomas</given-names></name><xref rid="cam470655-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="cam470655-cr-0010" contrib-type="author"><name><surname>Kunz</surname><given-names>Wolfgang G.</given-names></name><xref rid="cam470655-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="cam470655-cr-0011" contrib-type="author"><name><surname>Stutz</surname><given-names>Emanuel</given-names></name><xref rid="cam470655-aff-0009" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib id="cam470655-cr-0012" contrib-type="author"><name><surname>von Bergwelt&#x02010;Baildon</surname><given-names>Michael</given-names></name><xref rid="cam470655-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cam470655-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cam470655-cr-0013" contrib-type="author"><name><surname>Di Gioia</surname><given-names>Dorit</given-names></name><xref rid="cam470655-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cam470655-cr-0014" contrib-type="author"><name><surname>Lindner</surname><given-names>Lars H.</given-names></name><xref rid="cam470655-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="cam470655-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Internal Medicine III, University Hospital</named-content>
<institution>LMU Munich</institution>
<city>Munich</city>
<country country="DE">Germany</country>
</aff><aff id="cam470655-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">German Cancer Consortium (DKTK)</named-content>
<institution>Partner Site Munich</institution>
<city>Munich</city>
<country country="DE">Germany</country>
</aff><aff id="cam470655-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>Institute for Medical Information Processing, Biometry, and Epidemiology, University Hospital</institution>
<institution>LMU Munich</institution>
<city>Munich</city>
<country country="DE">Germany</country>
</aff><aff id="cam470655-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of General, Visceral and Transplantation Surgery, University Hospital</named-content>
<institution>LMU Munich</institution>
<city>Munich</city>
<country country="DE">Germany</country>
</aff><aff id="cam470655-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Orthopaedic Oncology, Department of Orthopaedics and Trauma Surgery, University Hospital</named-content>
<institution>LMU Munich</institution>
<city>Munich</city>
<country country="DE">Germany</country>
</aff><aff id="cam470655-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Department of Radiation Oncology, University Hospital</named-content>
<institution>LMU Munich</institution>
<city>Munich</city>
<country country="DE">Germany</country>
</aff><aff id="cam470655-aff-0007">
<label>
<sup>7</sup>
</label>
<named-content content-type="organisation-division">Institute of Pathology</named-content>
<institution>LMU Munich</institution>
<city>Munich</city>
<country country="DE">Germany</country>
</aff><aff id="cam470655-aff-0008">
<label>
<sup>8</sup>
</label>
<named-content content-type="organisation-division">Department of Radiology, University Hospital</named-content>
<institution>LMU Munich</institution>
<city>Munich</city>
<country country="DE">Germany</country>
</aff><aff id="cam470655-aff-0009">
<label>
<sup>9</sup>
</label>
<named-content content-type="organisation-division">Department of Radiation Oncology, Inselspital</named-content>
<institution>Bern University Hospital, University of Bern</institution>
<city>Bern</city>
<country country="CH">Switzerland</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold>
<break/>
Luc M. Berclaz (<email>luc.berclaz@med.uni-muenchen.de</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>25</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>14</volume><issue seq="420">4</issue><issue-id pub-id-type="doi">10.1002/cam4.v14.4</issue-id><elocation-id>e70655</elocation-id><history>
<date date-type="rev-recd"><day>19</day><month>11</month><year>2024</year></date>
<date date-type="received"><day>24</day><month>4</month><year>2024</year></date>
<date date-type="accepted"><day>25</day><month>1</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 Published by John Wiley & Sons Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">Cancer Medicine</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:CAM4-14-e70655.pdf"/><abstract><title>ABSTRACT</title><sec id="cam470655-sec-0001"><title>Background</title><p>Dacarbazine is currently considered the better combination partner for doxorubicin compared to ifosfamide for the treatment of leiomyosarcoma (LMS). Regional hyperthermia (RHT) combined with neoadjuvant chemotherapy has been shown to improve survival in patients with locally advanced high&#x02010;risk STS. We sought to evaluate the role of doxorubicin and dacarbazine (AD) versus doxorubicin and ifosfamide (AI) in combination with RHT in patients with LMS.</p></sec><sec id="cam470655-sec-0002"><title>Methods</title><p>Patients with locally advanced high&#x02010;grade LMS, including limited metastases, eligible for RHT and first&#x02010;line treatment with either AI&#x02009;+&#x02009;RHT or AD&#x02009;+&#x02009;RHT between 2014 and 2022 were retrospectively evaluated. Endpoints were progression&#x02010;free survival (PFS) and overall survival (OS). Patients were matched using propensity scores, which were estimated with a logistic regression model accounting for tumor site, presence of metastasis, surgery, and radiotherapy.</p></sec><sec id="cam470655-sec-0003"><title>Results</title><p>A total of 105 patients were included in this study, of which 101 were included in the propensity score&#x02010;matched cohort. In the matched cohort, treatment with AD&#x02009;+&#x02009;RHT was associated with a significantly improved PFS (HR 0.32, 95% CI 0.13&#x02013;0.74, <italic toggle="no">p</italic>&#x02009;=&#x02009;0.0081). Multivariable analysis revealed several significant predictors of PFS, including treatment with AD&#x02009;+&#x02009;RHT (HR 0.42, 95% CI 0.19&#x02013;0.92, <italic toggle="no">p</italic>&#x02009;=&#x02009;0.031).</p></sec><sec id="cam470655-sec-0004"><title>Conclusion</title><p>Treatment with AD&#x02009;+&#x02009;RHT showed improved PFS and better treatment tolerability compared to AI&#x02009;+&#x02009;RHT. Our results support the use of AD instead of AI for the treatment of patients with LMS in combination with RHT.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="cam470655-kwd-0001">chemotherapy</kwd><kwd id="cam470655-kwd-0002">leiomyosarcoma</kwd><kwd id="cam470655-kwd-0003">regional hyperthermia</kwd><kwd id="cam470655-kwd-0004">soft tissue sarcoma</kwd></kwd-group><counts><fig-count count="3"/><table-count count="4"/><page-count count="10"/><word-count count="5800"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:26.02.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="cam470655-ntgp-0001"><fn fn-type="funding" id="cam470655-note-0001"><p>
<bold>Funding:</bold> The authors received no specific funding for this work.</p></fn></fn-group></notes></front><body id="cam470655-body-0001"><sec id="cam470655-sec-0005"><label>1</label><title>Introduction</title><p>Soft tissue sarcomas (STS) are rare tumors with multiple distinct histopathological subtypes. They account for approximately 1% of adult malignancies [<xref rid="cam470655-bib-0001" ref-type="bibr">1</xref>]. Leiomyosarcoma (LMS) is among the most common histological subtypes, accounting for 10%&#x02013;20% of all STS. In patients with LMS and high&#x02010;risk features (G2/G3, &#x02265;&#x02009;5&#x02009;cm, deep to the fascia), prognosis is poor [<xref rid="cam470655-bib-0002" ref-type="bibr">2</xref>, <xref rid="cam470655-bib-0003" ref-type="bibr">3</xref>]. Due to their aggressive behavior, high&#x02010;grade uterine and extra&#x02010;uterine LMS show a high risk of recurrence of 50%&#x02013;70% or approximately 40% despite complete resection&#x000a0;[<xref rid="cam470655-bib-0002" ref-type="bibr">2</xref>, <xref rid="cam470655-bib-0004" ref-type="bibr">4</xref>, <xref rid="cam470655-bib-0005" ref-type="bibr">5</xref>]. Therefore, in locally advanced LMS, chemotherapy in addition to a radical surgical approach may be proposed for fit patients affected by disease at high risk of death, often described as a 10&#x02010;year overall survival (OS) of &#x0003c;&#x02009;60% [<xref rid="cam470655-bib-0006" ref-type="bibr">6</xref>, <xref rid="cam470655-bib-0007" ref-type="bibr">7</xref>]. For patients with advanced and metastatic LMS, chemotherapy is based on anthracyclines as a monotherapy or in combination with dacarbazine (AD), or in combination with ifosfamide (AI), with current data suggesting a limited effect of AI [<xref rid="cam470655-bib-0008" ref-type="bibr">8</xref>, <xref rid="cam470655-bib-0009" ref-type="bibr">9</xref>, <xref rid="cam470655-bib-0010" ref-type="bibr">10</xref>, <xref rid="cam470655-bib-0011" ref-type="bibr">11</xref>, <xref rid="cam470655-bib-0012" ref-type="bibr">12</xref>, <xref rid="cam470655-bib-0013" ref-type="bibr">13</xref>]. More recently, the combination of doxorubicin and trabectedin followed by trabectedin maintenance demonstrated favorable activity as first&#x02010;line therapy for metastatic and unresectable LMS [<xref rid="cam470655-bib-0014" ref-type="bibr">14</xref>, <xref rid="cam470655-bib-0015" ref-type="bibr">15</xref>]. In contrast, the first&#x02010;line combination of gemcitabine and docetaxel failed to demonstrate superiority compared to anthracycline&#x02010;based therapies [<xref rid="cam470655-bib-0016" ref-type="bibr">16</xref>, <xref rid="cam470655-bib-0017" ref-type="bibr">17</xref>, <xref rid="cam470655-bib-0018" ref-type="bibr">18</xref>, <xref rid="cam470655-bib-0019" ref-type="bibr">19</xref>].</p><p>As described in the ESMO&#x02010;EURACAN&#x02010;GENTURIS guidelines on STS, the addition of regional hyperthermia (RHT) to neoadjuvant chemotherapy is a feasible option [<xref rid="cam470655-bib-0006" ref-type="bibr">6</xref>]. This is mostly due to a large multicenter EORTC Phase III study that demonstrated a 10&#x02010;year OS benefit of 9.9% with chemotherapy and RHT compared to chemotherapy alone [<xref rid="cam470655-bib-0020" ref-type="bibr">20</xref>, <xref rid="cam470655-bib-0021" ref-type="bibr">21</xref>]. Synergistic effects with RHT are related to improved drug delivery into the tumor, increased drug cytotoxicity, direct thermal toxicity, and potential tumoricidal immune responses by increasing immune infiltrates and priming the tumor microenvironment [<xref rid="cam470655-bib-0022" ref-type="bibr">22</xref>, <xref rid="cam470655-bib-0023" ref-type="bibr">23</xref>, <xref rid="cam470655-bib-0024" ref-type="bibr">24</xref>]. The synergistic effect of RHT in combination with ifosfamide is well established, showing a thermal enhancement ratio from 1.52 to 3.6 [<xref rid="cam470655-bib-0022" ref-type="bibr">22</xref>, <xref rid="cam470655-bib-0025" ref-type="bibr">25</xref>, <xref rid="cam470655-bib-0026" ref-type="bibr">26</xref>, <xref rid="cam470655-bib-0027" ref-type="bibr">27</xref>]. In contrast, there is only limited data on the effect of RHT on the efficacy of dacarbazine [<xref rid="cam470655-bib-0028" ref-type="bibr">28</xref>, <xref rid="cam470655-bib-0029" ref-type="bibr">29</xref>]. In our institution, patients with locally advanced high&#x02010;grade STS, including limited metastases, have been routinely treated with pre&#x02010; or postoperative/additive chemotherapy with AI and RHT. In the year 2020, our standard protocol for LMS was changed to AD&#x02009;+&#x02009;RHT due to the promising results in the multicenter analysis conducted by D'Ambrosio et&#x000a0;al., which showed a favorable activity of AD in terms of overall response rate (ORR) and progression&#x02010;free survival (PFS) compared to AI and doxorubicin alone [<xref rid="cam470655-bib-0008" ref-type="bibr">8</xref>]. In this study, we sought to compare both protocols in a large and well&#x02010;characterized cohort.</p></sec><sec sec-type="materials-and-methods" id="cam470655-sec-0006"><label>2</label><title>Materials and Methods</title><sec id="cam470655-sec-0007"><label>2.1</label><title>Patient Selection</title><p>An exploratory retrospective cohort study design was chosen to address the research question. Eligible patients were &#x02265;&#x02009;18&#x02009;years of age and had pathologically confirmed LMS with high&#x02010;risk features (G2/G3, deep to the fascia). Clinical, pathological, and outcomes data were extracted from our clinical sarcoma database. Patients received a multimodal first&#x02010;line treatment including up to eight cycles of doxorubicin&#x02010;based chemotherapy in combination with either dacarbazine or ifosfamide between 2014 and 2022. Patients under 60&#x02009;years of age received 60&#x02009;mg/m<sup>2</sup> of doxorubicin per cycle and 9&#x02009;g/m<sup>2</sup> of ifosfamide (reduced to 6&#x02009;g/m<sup>2</sup> AI for cycles 5&#x02013;8) or 1200&#x02009;mg/m<sup>2</sup> of dacarbazine. The standard dose for patients older than 60&#x02009;years was 60&#x02009;mg/m<sup>2</sup> of doxorubicin combined with either 900&#x02009;mg/m<sup>2</sup> of dacarbazine or 6&#x02009;g/m<sup>2</sup> of ifosfamide per cycle. The doxorubicin dose of 60&#x02009;mg/m<sup>2</sup> was chosen to increase the number of chemotherapy cycles without reaching the maximal cumulative anthracycline dose while maximizing the local effect of RHT [<xref rid="cam470655-bib-0021" ref-type="bibr">21</xref>]. All patients were treated with chemotherapy in combination with RHT. RHT aiming for tumor temperatures elevating to 42&#x000b0;C&#x02013;43&#x000b0;C for 60&#x02009;min was given twice per AI or AD cycle. Quality and safety of hyperthermia were ensured by the European Society for Hyperthermic Oncology (ESHO) guidelines [<xref rid="cam470655-bib-0030" ref-type="bibr">30</xref>]. The BSD&#x02010;2000 hyperthermia system (PYREXAR Medical, Salt Lake City, UT, USA) was used. In patients with locally advanced disease, surgery was generally performed after four cycles of chemotherapy and RHT following discussion in our interdisciplinary tumor board. Patients with initial tumor resection received the complete treatment in an adjuvant (R0) or additive (R1/R2) approach. Radiotherapy was used in a pre&#x02010; or postoperative setting in patients with extremity sarcomas or in selected nonextremity cases to enhance local tumor control. In addition to chemotherapy and RHT, patients with evidence of limited metastases eligible for RHT were discussed in our interdisciplinary tumor board to evaluate potential local ablative therapies including radiotherapy and surgery. Patients who received both protocols (e.g., switch from AI to AD due to impaired renal function) had severe or uncontrolled concomitant disease or patients who had previously received chemotherapy were excluded from the analysis.</p></sec><sec id="cam470655-sec-0008"><label>2.2</label><title>Outcomes</title><p>The primary objective of this study was to explore the impact of AD and AI in combination with RHT as a first&#x02010;line treatment for locally advanced or metastatic LMS. Endpoints of this study included PFS and OS. The PFS duration was estimated by the time from the start of chemotherapy and RHT or surgery to first local or distant progression. OS was estimated by the time from the start of chemotherapy to death. In patients receiving preoperative chemotherapy, radiologic tumor response was assessed according to the RECIST 1.1 criteria after two cycles of chemotherapy [<xref rid="cam470655-bib-0031" ref-type="bibr">31</xref>]. RECIST evaluations were obtained by measuring the tumor's largest diameter, and measures were performed on the most convenient CT or MR sequence available. Outcomes were compared with radiologic response to chemotherapy. Because of the absence of randomization, matching of patients was performed by using a propensity score.</p></sec><sec id="cam470655-sec-0009"><label>2.3</label><title>Statistical Analysis</title><p>Continuous variables were compared using the Mann&#x02013;Whitney <italic toggle="yes">U</italic> test and categorical variables with the Fisher's exact test. Survival analyses were performed with Cox proportional hazards regression. The propensity score was estimated with logistic regression, and the data were matched with the optimal full matching method, in which all subjects received at least one match [<xref rid="cam470655-bib-0032" ref-type="bibr">32</xref>]. All <italic toggle="yes">p</italic>&#x02010;values&#x02009;&#x02264;&#x02009;0.05 were considered significant.</p><p>All statistical analyses were done using the statistical software R (version 4.4.1). The R package <italic toggle="yes">MatchIt</italic> (version 4.5.5) was used for propensity score matching and the package <italic toggle="yes">adjustedCurves</italic> (version 0.11.2) for plotting the adjusted Kaplan&#x02013;Meier curves.</p></sec></sec><sec sec-type="results" id="cam470655-sec-0010"><label>3</label><title>Results</title><sec id="cam470655-sec-0011"><label>3.1</label><title>Patient Cohort</title><p>One hundred and five patients treated between 2014 and 2022 were analyzed (Figure&#x000a0;<xref rid="cam470655-fig-0001" ref-type="fig">1</xref>). The patient and tumor characteristics of the study cohort are summarized in Table&#x000a0;<xref rid="cam470655-tbl-0001" ref-type="table">1</xref>. Sixty&#x02010;three patients were treated with AI&#x02009;+&#x02009;RHT, whereas 42 patients received AD&#x02009;+&#x02009;RHT. The rate of metastasis at the beginning of chemotherapy was higher in the AD&#x02009;+&#x02009;RHT group (50% vs. 19%, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.0012). LMS of the extremity was more common in the AI&#x02009;+&#x02009;RHT group (21% vs. 2%, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.0020). Furthermore, surgery was more often performed in the AI&#x02009;+&#x02009;RHT group (97% vs. 81%, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.013). More patients received pre&#x02010; or postoperative radiotherapy in the AI group due to the higher rate of extremity LMS (33% vs. 9%, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.0044).</p><fig position="float" fig-type="FIGURE" id="cam470655-fig-0001"><label>FIGURE 1</label><caption><p>Flowchart of evaluated patients.</p></caption><graphic xlink:href="CAM4-14-e70655-g002" position="anchor" id="jats-graphic-1"/></fig><table-wrap position="float" id="cam470655-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Patient characteristics.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" colspan="2" valign="bottom" rowspan="1">Value</th><th align="center" valign="bottom" rowspan="1" colspan="1">AI</th><th align="center" valign="bottom" rowspan="1" colspan="1">AD</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Age</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Median (range)</td><td align="center" valign="top" rowspan="1" colspan="1">57 (34&#x02013;77)</td><td align="center" valign="top" rowspan="1" colspan="1">58 (25&#x02013;83)</td><td align="center" valign="top" rowspan="1" colspan="1">0.39</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Sex</td><td align="center" valign="top" rowspan="1" colspan="1">Female</td><td align="center" rowspan="2" valign="top" colspan="1">
<italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">45 (71)</td><td align="center" valign="top" rowspan="1" colspan="1">35 (83)</td><td align="center" rowspan="2" valign="top" colspan="1">0.24</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Male</td><td align="center" valign="top" rowspan="1" colspan="1">18 (29)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (17)</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Recurrent tumor</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="2" valign="top" colspan="1">
<italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (19)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (29)</td><td align="center" rowspan="2" valign="top" colspan="1">0.34</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">51 (81)</td><td align="center" valign="top" rowspan="1" colspan="1">30 (71)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Largest diameter</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Median (range)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (3&#x02013;29)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (4&#x02013;24)</td><td align="center" valign="top" rowspan="1" colspan="1">0.79</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Histology</td><td align="center" valign="top" rowspan="1" colspan="1">Uterine LMS</td><td align="center" rowspan="2" valign="top" colspan="1">
<italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">24 (38)</td><td align="center" valign="top" rowspan="1" colspan="1">13 (31)</td><td align="center" rowspan="2" valign="top" colspan="1">0.53</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Non&#x02010;uterine LMS</td><td align="center" valign="top" rowspan="1" colspan="1">39 (62)</td><td align="center" valign="top" rowspan="1" colspan="1">29 (69)</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Metastasis at beginning of chemotherapy</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="2" valign="top" colspan="1">
<italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (19)</td><td align="center" valign="top" rowspan="1" colspan="1">21 (50)</td><td align="center" rowspan="2" valign="top" colspan="1">0.0012</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">51 (81)</td><td align="center" valign="top" rowspan="1" colspan="1">21 (50)</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Grade</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" rowspan="2" valign="top" colspan="1">
<italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">31 (49)</td><td align="center" valign="top" rowspan="1" colspan="1">22 (52)</td><td align="center" rowspan="2" valign="top" colspan="1">0.84</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">32 (51)</td><td align="center" valign="top" rowspan="1" colspan="1">20 (48)</td></tr><tr><td align="left" rowspan="4" valign="top" colspan="1">Site of primary tumor</td><td align="center" valign="top" rowspan="1" colspan="1">Extremity</td><td align="center" rowspan="4" valign="top" colspan="1">
<italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">13 (21)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (2)</td><td align="center" rowspan="4" valign="top" colspan="1">0.0085</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Intraabdominal</td><td align="center" valign="top" rowspan="1" colspan="1">48 (76)</td><td align="center" valign="top" rowspan="1" colspan="1">41 (98)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Trunk</td><td align="center" valign="top" rowspan="1" colspan="1">1 (2)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Head and neck</td><td align="center" valign="top" rowspan="1" colspan="1">1 (2)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" rowspan="4" valign="top" colspan="1">Site of metastases at beginning of chemotherapy</td><td align="center" valign="top" rowspan="1" colspan="1">Liver</td><td align="center" rowspan="4" valign="top" colspan="1">
<italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (17)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (33)</td><td align="center" rowspan="4" valign="top" colspan="1">0.21</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Pulmonary</td><td align="center" valign="top" rowspan="1" colspan="1">8 (67)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (29)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Liver&#x02009;+&#x02009;pulmonary</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (10)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Other</td><td align="center" valign="top" rowspan="1" colspan="1">2 (17)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (29)</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Surgery</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="2" valign="top" colspan="1">
<italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">61 (97)</td><td align="center" valign="top" rowspan="1" colspan="1">34 (81)</td><td align="center" rowspan="2" valign="top" colspan="1">0.013</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">2 (3)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (19)</td></tr><tr><td align="left" rowspan="4" valign="top" colspan="1">Extent of surgery</td><td align="center" valign="top" rowspan="1" colspan="1">R0</td><td align="center" rowspan="4" valign="top" colspan="1">
<italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">40 (66)</td><td align="center" valign="top" rowspan="1" colspan="1">19 (58)</td><td align="center" rowspan="4" valign="top" colspan="1">0.66</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">R1</td><td align="center" valign="top" rowspan="1" colspan="1">11 (18)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (27)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">R2</td><td align="center" valign="top" rowspan="1" colspan="1">1 (2)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">RX</td><td align="center" valign="top" rowspan="1" colspan="1">9 (15x)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (12)</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Radiotherapy</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="2" valign="top" colspan="1">
<italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">21 (33)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (9)</td><td align="center" rowspan="2" valign="top" colspan="1">0.0044</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">42 (67)</td><td align="center" valign="top" rowspan="1" colspan="1">38 (91)</td></tr><tr><td align="left" rowspan="3" valign="top" colspan="1">Radiologic response to preoperative CT</td><td align="center" valign="top" rowspan="1" colspan="1">PR</td><td align="center" rowspan="3" valign="top" colspan="1">
<italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (29)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (19)</td><td align="center" rowspan="3" valign="top" colspan="1">0.52</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">SD</td><td align="center" valign="top" rowspan="1" colspan="1">16 (57)</td><td align="center" valign="top" rowspan="1" colspan="1">13 (50)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">PD</td><td align="center" valign="top" rowspan="1" colspan="1">4 (14)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (31)</td></tr></tbody></table></table-wrap></sec><sec id="cam470655-sec-0012"><label>3.2</label><title>Chemotherapy Data</title><p>The median number of chemotherapy cycles was similar in both treatment arms (median 8&#x02009;cycles, range 1&#x02013;8, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.17) (Table&#x000a0;<xref rid="cam470655-tbl-0002" ref-type="table">2</xref>). The number of dose reductions, mostly due to hematological toxicity, was significantly higher in the AI arm (33% vs. 10%, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.0051). The rate of regular treatment completion after 8&#x02009;cycles of chemotherapy and RHT was similar in both subgroups (60% vs. 51%, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.078). The rate of treatment interruption due to disease progression was higher in patients with metastatic disease at the beginning of treatment (39% vs. 11%, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.0014). Three patients in the AD arm began their treatment with chemotherapy only and therefore received a higher doxorubicin starting dose (75&#x02009;mg/m<sup>2</sup>). The dose was reduced after the addition of RHT in the following cycles.</p><table-wrap position="float" id="cam470655-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Chemotherapy data.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" colspan="2" valign="bottom" rowspan="1">Value</th><th align="center" valign="bottom" rowspan="1" colspan="1">AI</th><th align="center" valign="bottom" rowspan="1" colspan="1">AD</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Chemotherapy cycles</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Median (range)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (1&#x02013;8)</td><td align="center" valign="top" rowspan="1" colspan="1">7.5 (2&#x02013;8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.17</td></tr><tr><td align="left" rowspan="3" valign="top" colspan="1">Distribution of chemotherapy cycles in patients without surgery</td><td align="center" valign="top" rowspan="1" colspan="1">1&#x02013;4</td><td align="center" rowspan="3" valign="top" colspan="1">
<italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (50)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (75)</td><td align="center" rowspan="3" valign="top" colspan="1">&#x0003e;&#x02009;0.999</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">5&#x02013;7</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">1 (50)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (25)</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Preoperative chemotherapy</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="2" valign="top" colspan="1">
<italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">28 (44)</td><td align="center" valign="top" rowspan="1" colspan="1">26 (62)</td><td align="center" rowspan="2" valign="top" colspan="1">0.11</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">35 (56)</td><td align="center" valign="top" rowspan="1" colspan="1">16 (38)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Number of preoperative cycles</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Median (range)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (1&#x02013;8)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (2&#x02013;8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.92</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Distribution of preoperative chemotherapy cycles</td><td align="center" valign="top" rowspan="1" colspan="1">1&#x02013;3</td><td align="center" rowspan="2" valign="top" colspan="1">
<italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (19)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (28)</td><td align="center" rowspan="2" valign="top" colspan="1">0.72</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">4&#x02013;8</td><td align="center" valign="top" rowspan="1" colspan="1">21 (81)</td><td align="center" valign="top" rowspan="1" colspan="1">13 (72)</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Postoperative chemotherapy</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="2" valign="top" colspan="1">
<italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">50 (79)</td><td align="center" valign="top" rowspan="1" colspan="1">27 (64)</td><td align="center" rowspan="2" valign="top" colspan="1">0.12</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">13 (21)</td><td align="center" valign="top" rowspan="1" colspan="1">15 (36)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Number of postoperative cycles</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Median (range)</td><td align="center" valign="top" rowspan="1" colspan="1">7.5 (2&#x02013;8)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (1&#x02013;8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.095</td></tr><tr><td align="left" rowspan="3" valign="top" colspan="1">Distribution of postoperative cycles in patients with primary surgery</td><td align="center" valign="top" rowspan="1" colspan="1">1&#x02013;4</td><td align="center" rowspan="3" valign="top" colspan="1">
<italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (14)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (21)</td><td align="center" rowspan="3" valign="top" colspan="1">0.72</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">5&#x02013;7</td><td align="center" valign="top" rowspan="1" colspan="1">6 (17)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (21)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">25 (69)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (57)</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Distribution of postoperative cycles in patients with surgery after chemotherapy</td><td align="center" valign="top" rowspan="1" colspan="1">1&#x02013;3</td><td align="center" rowspan="2" valign="top" colspan="1">
<italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (33)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (42)</td><td align="center" rowspan="2" valign="top" colspan="1">0.71</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">4&#x02013;6</td><td align="center" valign="top" rowspan="1" colspan="1">10 (67)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (58)</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Doxorubicin starting dose</td><td align="center" valign="top" rowspan="1" colspan="1">60</td><td align="center" rowspan="2" valign="top" colspan="1">
<italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">63 (100)</td><td align="center" valign="top" rowspan="1" colspan="1">39 (93)</td><td align="center" rowspan="2" valign="top" colspan="1">0.061</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">75</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (7)</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Ifosfamide starting dose (g/m<sup>2</sup>)</td><td align="center" valign="top" rowspan="1" colspan="1">6</td><td align="center" rowspan="2" valign="top" colspan="1">
<italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">34 (54)</td><td align="center" rowspan="2" valign="top" colspan="1"/><td align="center" rowspan="2" valign="top" colspan="1"/></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">29 (46)</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">DTIC starting dose (g/m<sup>2</sup>)</td><td align="center" valign="top" rowspan="1" colspan="1">900</td><td align="center" rowspan="2" valign="top" colspan="1">
<italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="2" valign="top" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">17 (40)</td><td align="center" rowspan="2" valign="top" colspan="1"/></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">1200</td><td align="center" valign="top" rowspan="1" colspan="1">25 (60)</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Dose reduction</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="2" valign="top" colspan="1">
<italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">21 (33)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (10)</td><td align="center" rowspan="2" valign="top" colspan="1">0.0051</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">42 (67)</td><td align="center" valign="top" rowspan="1" colspan="1">38 (90)</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Reason for dose reduction</td><td align="center" valign="top" rowspan="1" colspan="1">Hematological toxicity</td><td align="center" rowspan="2" valign="top" colspan="1">
<italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">20 (32)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (7)</td><td align="center" rowspan="2" valign="top" colspan="1">0.0038</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Other toxicity</td><td align="center" valign="top" rowspan="1" colspan="1">1 (2)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (2)</td></tr><tr><td align="left" rowspan="5" valign="top" colspan="1">Reason for interruption</td><td align="center" valign="top" rowspan="1" colspan="1">Treatment completed</td><td align="center" rowspan="5" valign="top" colspan="1">
<italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">38 (60)</td><td align="center" valign="top" rowspan="1" colspan="1">22 (51)</td><td align="center" rowspan="5" valign="top" colspan="1">0.078</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Disease progression</td><td align="center" valign="top" rowspan="1" colspan="1">9 (14)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (29)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Toxicity</td><td align="center" valign="top" rowspan="1" colspan="1">9 (14)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (10)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Physician's choice</td><td align="center" valign="top" rowspan="1" colspan="1">5 (8)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Patient refusal</td><td align="center" valign="top" rowspan="1" colspan="1">2 (4)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (10)</td></tr></tbody></table></table-wrap></sec><sec id="cam470655-sec-0013"><label>3.3</label><title>Patient Outcomes in the Unmatched Population</title><p>For the 105 patients included in this study, the median follow&#x02010;up (FU) was 3.97&#x02009;years. The overall 2&#x02010;year OS and 2&#x02010;year PFS were 84.5% (95% CI 77.2%&#x02013;92.3%) and 50.3% (95% CI 41.0%&#x02013;61.7%), respectively. The median FU was 1.57&#x02009;years in the AD arm and 5.43&#x02009;years in the AI arm. The 2&#x02010;year OS in the AI&#x02009;+&#x02009;RHT group was 88.7% (95% CI 81.2%&#x02013;97.6%) versus 73.9% (95% CI 58.3%&#x02013;93.6%) in the AD&#x02009;+&#x02009;RHT group, respectively (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.21). The 2&#x02010;year PFS was 54.9% (95% CI 43.8%&#x02013;68.8%) in the AI&#x02009;+&#x02009;RHT group versus 43.7% (95% CI 28.5%&#x02013;67.0%) in the AD&#x02009;+&#x02009;RHT group (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.115) (Figure&#x000a0;<xref rid="cam470655-fig-0002" ref-type="fig">2</xref>). A trend toward poorer OS was visible in the AD&#x02009;+&#x02009;RHT group in patients receiving 1&#x02013;4&#x02009;cycles of chemotherapy (OS: HR 2.77, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.073, PFS: HR 1.76, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.18).</p><fig position="float" fig-type="FIGURE" id="cam470655-fig-0002"><label>FIGURE 2</label><caption><p>Overall survival (OS) and progression&#x02010;free survival (PFS) in the unmatched population.</p></caption><graphic xlink:href="CAM4-14-e70655-g003" position="anchor" id="jats-graphic-3"/></fig></sec><sec id="cam470655-sec-0014"><label>3.4</label><title>Patient Outcomes in the Matched Population</title><p>Patients were matched according to their propensity scores, which were estimated with a logistic regression model accounting for significantly different baseline characteristics in both subgroups (tumor site, surgical resection, radiotherapy, and metastasis at the beginning of chemotherapy). Information on radiotherapy was missing for four patients; thus, the matched cohort consisted of 101 patients. The performance of the propensity score matching and the baseline characteristics of the matched cohorts are included in Table&#x000a0;<xref rid="cam470655-supitem-0001" ref-type="supplementary-material">S1</xref> and Figures&#x000a0;<xref rid="cam470655-supitem-0001" ref-type="supplementary-material">S1&#x02013;S5</xref>. Tumor site, metastasis at the beginning of chemotherapy, extent of surgery, and radiotherapy remained statistically significant predictors of PFS in the matched population (Table&#x000a0;<xref rid="cam470655-tbl-0003" ref-type="table">3</xref>). The addition of radiotherapy was associated with both an improved local (HR 0.34, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.0094) and distant PFS (HR 0.48, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.016). Treatment with AD&#x02009;+ RHT was significantly associated with a better PFS (HR 0.32, 95% CI 0.13&#x02013;0.74, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.0081). This effect was not maintained for OS (HR 0.43, 95% CI 0.11&#x02013;1.73, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.23) (Figure&#x000a0;<xref rid="cam470655-fig-0003" ref-type="fig">3</xref>). In an exploratory subgroup analysis within the matched cohort, treatment with AD&#x02009;+&#x02009;RHT was not associated with better PFS/OS after separating the patients according to localized and metastatic disease (Tables&#x000a0;<xref rid="cam470655-supitem-0001" ref-type="supplementary-material">S2&#x02013;S5</xref>).</p><table-wrap position="float" id="cam470655-tbl-0003" content-type="TABLE"><label>TABLE 3</label><caption><p>Significant predictors of progression&#x02010;free survival (PFS) in the propensity score&#x02010;matched population.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Factor</th><th align="center" valign="bottom" rowspan="1" colspan="1">Strata</th><th align="center" valign="bottom" rowspan="1" colspan="1">Significance</th><th align="center" valign="bottom" rowspan="1" colspan="1">Hazard ratio</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Treatment regimen</td><td align="center" valign="top" rowspan="1" colspan="1">AD vs. AI</td><td align="center" valign="top" rowspan="1" colspan="1">0.0081</td><td align="center" valign="top" rowspan="1" colspan="1">0.32 (0.13&#x02013;0.74)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tumor site</td><td align="center" valign="top" rowspan="1" colspan="1">Extremity vs. non&#x02010;extremity</td><td align="center" valign="top" rowspan="1" colspan="1">0.0024</td><td align="center" valign="top" rowspan="1" colspan="1">0.45 (0.27&#x02013;0.76)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Metastasis at the beginning of treatment</td><td align="center" valign="top" rowspan="1" colspan="1">Yes vs. no</td><td align="center" valign="top" rowspan="1" colspan="1">2.5&#x02219;10<sup>&#x02212;5</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">4.35 (2.17&#x02013;8.33)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Surgical resection</td><td align="center" valign="top" rowspan="1" colspan="1">Yes vs. no</td><td align="center" valign="top" rowspan="1" colspan="1">1.4&#x02219;10<sup>&#x02212;6</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>0.18 (0.09&#x02013;0.34)</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Radiotherapy</td><td align="center" valign="top" rowspan="1" colspan="1">Yes vs. no</td><td align="center" valign="top" rowspan="1" colspan="1">0.020</td><td align="center" valign="top" rowspan="1" colspan="1">0.60 (0.39&#x02013;0.92)</td></tr></tbody></table></table-wrap><fig position="float" fig-type="FIGURE" id="cam470655-fig-0003"><label>FIGURE 3</label><caption><p>Overall survival (OS) and progression&#x02010;free survival (PFS) in the propensity score&#x02010;matched population.</p></caption><graphic xlink:href="CAM4-14-e70655-g001" position="anchor" id="jats-graphic-5"/></fig></sec><sec id="cam470655-sec-0015"><label>3.5</label><title>Predictive Parameters</title><p>In the unmatched cohort, after adjustment for treatment groups, significant predictors of poor OS were the presence of metastasis at the beginning of chemotherapy (HR 3.45, 95% CI 1.50&#x02013;7.95, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.0036), larger tumor size (HR 1.08, 95% CI 1.02&#x02013;1.15, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.0081), progressive disease (PD) according to RECIST 1.1 (HR 13.0, 95% CI 1.56&#x02013;108.51, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.018), and incomplete resection (R1&#x02010;Rx vs. R0, HR 5.93, 95% CI 2.26&#x02013;15.52, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.00029). Regarding PFS, in addition to the presence of metastasis, PD according to RECIST, and incomplete resection, the presence of recurrent disease was predictive of a shorter PFS (HR 2.70, 95% CI 1.55&#x02013;4.69, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.00045). Radiotherapy was correlated with an improved PFS (HR 0.51, 95% CI 0.26&#x02013;0.97, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.041). The administration of 5&#x02013;8&#x02009;cycles of chemotherapy predicted a better overall and PFS compared to 1&#x02013;4&#x02009;cycles of chemotherapy (OS: HR 0.16, 95% CI 0.07&#x02013;0.35, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.0001; PFS: HR 0.25, 95% CI 0.14&#x02013;0.42, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.0001).</p></sec><sec id="cam470655-sec-0016"><label>3.6</label><title>Multivariable Analysis</title><p>The results of multivariable analysis in the unmatched cohort are summarized in Table&#x000a0;<xref rid="cam470655-tbl-0004" ref-type="table">4</xref>. Systemic therapy with AD&#x02009;+&#x02009;RHT, intermediate grade (G2) according to FNCLCC, and surgical resection were predictive of favorable PFS in the multivariable analysis. Poor PFS and a trend toward poor OS were visible in patients with the presence of metastasis at the beginning of systemic therapy.</p><table-wrap position="float" id="cam470655-tbl-0004" content-type="TABLE"><label>TABLE 4</label><caption><p>Multivariable analysis of progression&#x02010;free survival (PFS) and overall survival (OS).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">Factor</th><th align="center" rowspan="2" valign="bottom" colspan="1">Strata</th><th align="center" colspan="2" valign="bottom" rowspan="1">PFS</th><th align="center" colspan="2" valign="bottom" rowspan="1">OS</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">Significance</th><th align="center" valign="bottom" rowspan="1" colspan="1">Hazard ratio</th><th align="center" valign="bottom" rowspan="1" colspan="1">Significance</th><th align="center" valign="bottom" rowspan="1" colspan="1">Hazard ratio</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Treatment regimen</td><td align="center" valign="top" rowspan="1" colspan="1">AD vs. AI</td><td align="center" valign="top" rowspan="1" colspan="1">0.031</td><td align="center" valign="top" rowspan="1" colspan="1">0.42 (0.19&#x02013;0.92)</td><td align="center" valign="top" rowspan="1" colspan="1">0.43</td><td align="center" valign="top" rowspan="1" colspan="1">0.61 (0.18&#x02013;2.08)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.14</td><td align="center" valign="top" rowspan="1" colspan="1">1.02 (0.99&#x02013;1.05)</td><td align="center" valign="top" rowspan="1" colspan="1">0.27</td><td align="center" valign="top" rowspan="1" colspan="1">1.03 (0.98&#x02013;1.07)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex</td><td align="center" valign="top" rowspan="1" colspan="1">Female vs. male</td><td align="center" valign="top" rowspan="1" colspan="1">0.61</td><td align="center" valign="top" rowspan="1" colspan="1">0.82 (0.39&#x02013;1.75)</td><td align="center" valign="top" rowspan="1" colspan="1">0.61</td><td align="center" valign="top" rowspan="1" colspan="1">0.74 (0.23&#x02013;2.34)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Histology</td><td align="center" valign="top" rowspan="1" colspan="1">Uterine vs. non&#x02010;uterine</td><td align="center" valign="top" rowspan="1" colspan="1">0.88</td><td align="center" valign="top" rowspan="1" colspan="1">1.05 (0.53&#x02013;2.07)</td><td align="center" valign="top" rowspan="1" colspan="1">0.47</td><td align="center" valign="top" rowspan="1" colspan="1">1.45 (0.53&#x02013;3.96)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Grading</td><td align="center" valign="top" rowspan="1" colspan="1">G2 vs. G3</td><td align="center" valign="top" rowspan="1" colspan="1">0.031</td><td align="center" valign="top" rowspan="1" colspan="1">0.50 (0.26&#x02013;0.94)</td><td align="center" valign="top" rowspan="1" colspan="1">0.33</td><td align="center" valign="top" rowspan="1" colspan="1">0.64 (0.26&#x02013;1.58)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tumor site</td><td align="center" valign="top" rowspan="1" colspan="1">Extremity vs. non&#x02010;extremity</td><td align="center" valign="top" rowspan="1" colspan="1">0.17</td><td align="center" valign="top" rowspan="1" colspan="1">0.53 (0.21&#x02013;1.32)</td><td align="center" valign="top" rowspan="1" colspan="1">0.64</td><td align="center" valign="top" rowspan="1" colspan="1">0.71 (0.17&#x02013;2.99)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Metastasis at beginning of treatment</td><td align="center" valign="top" rowspan="1" colspan="1">Yes vs. no</td><td align="center" valign="top" rowspan="1" colspan="1">0.00015</td><td align="center" valign="top" rowspan="1" colspan="1">4.17 (1.99&#x02013;8.73)</td><td align="center" valign="top" rowspan="1" colspan="1">0.066</td><td align="center" valign="top" rowspan="1" colspan="1">2.64 (0.94&#x02013;7.44)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Surgery</td><td align="center" valign="top" rowspan="1" colspan="1">Yes vs. no</td><td align="center" valign="top" rowspan="1" colspan="1">0.042</td><td align="center" valign="top" rowspan="1" colspan="1">0.36 (0.14&#x02013;0.96)</td><td align="center" valign="top" rowspan="1" colspan="1">0.088</td><td align="center" valign="top" rowspan="1" colspan="1">0.30 (0.07&#x02013;1.20)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Radiotherapy</td><td align="center" valign="top" rowspan="1" colspan="1">Yes vs. no</td><td align="center" valign="top" rowspan="1" colspan="1">0.23</td><td align="center" valign="top" rowspan="1" colspan="1">0.61 (0.27&#x02013;1.38)</td><td align="center" valign="top" rowspan="1" colspan="1">0.35</td><td align="center" valign="top" rowspan="1" colspan="1">0.52 (0.13&#x02013;2.05)</td></tr></tbody></table></table-wrap></sec></sec><sec sec-type="discussion" id="cam470655-sec-0017"><label>4</label><title>Discussion</title><p>This is the first study to compare AD&#x02009;+&#x02009;RHT versus AI&#x02009;+&#x02009;RHT as a first&#x02010;line treatment in patients with locally advanced high&#x02010;grade LMS, including limited metastases. Our results demonstrate a PFS benefit and favorable toxicity profile in patients receiving AD&#x02009;+&#x02009;RHT. Historically, the addition of ifosfamide to anthracycline&#x02010;containing protocols did not have a significant impact on patient outcomes in LMS. Sleijfer et&#x000a0;al. identified LMS patients as a group who benefited less from ifosfamide&#x02010;based therapy compared to doxorubicin alone [<xref rid="cam470655-bib-0033" ref-type="bibr">33</xref>]. In addition, Le Cesne et&#x000a0;al. demonstrated an objective tumor regression in only 14% of LMS patients, which was exceptionally low compared to other histological subtypes [<xref rid="cam470655-bib-0034" ref-type="bibr">34</xref>]. D'Ambrosio et&#x000a0;al. further questioned the effectiveness of ifosfamide and demonstrated the lowest response rate and median OS rates in patients with advanced and metastatic LMS receiving a combination of doxorubicin and ifosfamide [<xref rid="cam470655-bib-0008" ref-type="bibr">8</xref>]. Due to the retrospective nature of all mentioned studies and missing prospective trials, the final role of AI in LMS is still not fully understood. Conflicting results such as a trend toward improved PFS in the AI group compared to doxorubicin alone in the D'Ambrosio et&#x000a0;al. study and missing differences in OS in the adjusted analyses make a correct interpretation difficult. In addition, patients only received a median number of 3&#x02009;cycles of AI compared to 6&#x02009;cycles of AD and tumor extent remained unbalanced in the AI arm after propensity score matching, which underlines basic differences in the patient cohorts. With many institutions involved in their multicenter study and therefore potentially center&#x02010;specific standards, there could be possible bias in the selection of patients for anthracycline monotherapy or the combination arms with ifosfamide or dacarbazine. The limited data on chemotherapy in LMS support the effort to conduct prospective trials of different anthracycline&#x02010;based chemotherapy regimens, such as the recent LMS04 trial, in patients with LMS [<xref rid="cam470655-bib-0015" ref-type="bibr">15</xref>].</p><p>An important difference in our study and why we hypothesized that AI&#x02009;+ RHT might be of value in LMS is the synergistic role of RHT with alkylating agents such as ifosfamide. Ifosfamide is infused at a time point when the tumor has reached a temperature of 40&#x000b0;C&#x02013;43.0&#x000b0;C, providing higher drug concentration due to increased perfusion together with increased cytotoxicity [<xref rid="cam470655-bib-0027" ref-type="bibr">27</xref>, <xref rid="cam470655-bib-0035" ref-type="bibr">35</xref>]. On the other hand, there is only limited data on the cytotoxic effect of dacarbazine in concomitant application with RHT. Although preclinical data suggest a synergistic effect between dacarbazine and hyperthermia, the previous Phase&#x02010;III trial on the combination of chemotherapy and RHT only included patients treated with doxorubicin, ifosfamide, and etoposide [<xref rid="cam470655-bib-0020" ref-type="bibr">20</xref>, <xref rid="cam470655-bib-0022" ref-type="bibr">22</xref>, <xref rid="cam470655-bib-0025" ref-type="bibr">25</xref>, <xref rid="cam470655-bib-0026" ref-type="bibr">26</xref>, <xref rid="cam470655-bib-0027" ref-type="bibr">27</xref>, <xref rid="cam470655-bib-0028" ref-type="bibr">28</xref>, <xref rid="cam470655-bib-0029" ref-type="bibr">29</xref>]. The significant PFS benefit of AD&#x02009;+&#x02009;RHT in the multivariable analysis and the matched population and promising survival data in our patient cohort support current preclinical data and the potential regarding the combination of dacarbazine and RHT. A subsequent analysis with a larger and more homogenous patient cohort is necessary to confirm the value of AD&#x02009;+ RHT in this patient subgroup.</p><p>The administration of 5&#x02013;8&#x02009;cycles of chemotherapy and RHT predicted a better OS and PFS compared to 1&#x02013;4&#x02009;cycles of therapy. The most common reasons for receiving fewer than 8&#x02009;cycles of chemotherapy and RHT in our cohort were disease progression and treatment toxicity, which explains the better outcome in patients receiving a higher number of treatment cycles and an inevitable positive selection of patients in this subgroup. Our findings, however, pose a much&#x02010;debated question regarding the optimal number of neoadjuvant chemotherapy cycles in STS, including LMS. Gronchi et&#x000a0;al. demonstrated a noninferiority of three preoperative cycles of AI chemotherapy compared to three preoperative and two postoperative AI cycles in localized high&#x02010;risk STS [<xref rid="cam470655-bib-0036" ref-type="bibr">36</xref>, <xref rid="cam470655-bib-0037" ref-type="bibr">37</xref>]. D'Ambrosio et&#x000a0;al. demonstrated a more favorable therapy adherence for AD versus AI, resulting in patients receiving a median number of 6&#x02009;cycles of AD compared to a median number of 3&#x02009;cycles of AI, which was associated with improved outcome and highlights our findings [<xref rid="cam470655-bib-0008" ref-type="bibr">8</xref>]. The optimal number of chemotherapy cycles with AD in patients with LMS should be evaluated in prospective trials.</p><p>Limitations of this study include the retrospective design and differences in baseline characteristics in both subgroups. FU in patients who received AD&#x02009;+&#x02009;RHT is limited, as our therapy protocol was switched from AI&#x02009;+&#x02009;RHT to AD&#x02009;+&#x02009;RHT in 2020, which results in a potential overestimation of survival outcomes in the AD arm. Data on OS are immature and will be presented with a longer FU in a subsequent analysis. In addition, as a significant number of patients with high&#x02010;risk LMS routinely underwent chemotherapy and RHT with curative intent and patients with diffuse metastatic disease more often received chemotherapy without RHT, treatment outcomes in this study are not easily comparable to previous literature on chemotherapy in more advanced and mostly metastatic LMS. The preliminary results of this study are hypothesis generating and should be interpreted with caution. On the basis of the results of this large single&#x02010;center analysis, we continue to apply AD&#x02009;+&#x02009;RHT in high&#x02010;risk LMS. In addition to the improved PFS in the propensity score&#x02010;matched population and the multivariable analysis, the lower rate of treatment toxicities is an important advantage of this regimen. A subsequent analysis with a longer FU, higher case numbers, and a more homogeneous cohort regarding metastasized vs. non&#x02010;metastasized patients and site of primary tumor should be conducted in the future.</p></sec><sec sec-type="conclusions" id="cam470655-sec-0018"><label>5</label><title>Conclusion</title><p>In conclusion, the results of this study raise unanswered questions about the optimal systemic treatment of patients with advanced LMS and the potential effect of RHT in increasing the effectiveness of chemotherapy with AD. The combination of AD&#x02009;+ RHT is well tolerated and potentially superior to AI&#x02009;+&#x02009;RHT, with promising results in the matched patient cohort and the multivariable analysis. A secondary analysis should be conducted in the future due to the limited FU in the patient group receiving AD&#x02009;+&#x02009;RHT. The nature of our results supports the effort to conduct prospective trials of different anthracycline&#x02010;based chemotherapy regimens in patients with LMS.</p></sec><sec id="cam470655-sec-0025"><title>Author Contributions</title><p>
<bold>Luc M. Berclaz:</bold> conceptualization (equal), data curation (equal), formal analysis (equal), investigation (equal), methodology (equal), writing &#x02013; original draft (lead). <bold>Vindi Jurinovic:</bold> data curation (equal), formal analysis (equal), software (equal), visualization (equal). <bold>Anton Burkhard&#x02010;Meier:</bold> writing &#x02013; review and editing (equal). <bold>Sultan Abdel&#x02010;Rahman:</bold> data curation (equal), project administration (equal), writing &#x02013; review and editing (equal). <bold>Markus Albertsmeier:</bold> writing &#x02013; review and editing (equal). <bold>Alexander Klein:</bold> writing &#x02013; review and editing (equal). <bold>Hans Roland D&#x000fc;rr:</bold> writing &#x02013; review and editing (equal). <bold>Nina&#x02010;Sophie Schmidt&#x02010;Hegemann:</bold> writing &#x02013; review and editing (equal). <bold>Thomas Kn&#x000f6;sel:</bold> writing &#x02013; review and editing (equal). <bold>Wolfgang G. Kunz:</bold> writing &#x02013; review and editing (equal). <bold>Emanuel Stutz:</bold> writing &#x02013; review and editing (equal). <bold>Michael von Bergwelt&#x02010;Baildon:</bold> writing &#x02013; review and editing (equal). <bold>Dorit Di Gioia:</bold> investigation (equal), methodology (equal), writing &#x02013; review and editing (equal). <bold>Lars H. Lindner:</bold> funding acquisition (equal), investigation (equal), methodology (equal), resources (equal), writing &#x02013; review and editing (equal).</p></sec><sec id="cam470655-sec-0020"><title>
<styled-content style="fixed-case" toggle="no">Ethics</styled-content> Statement</title><p>The Internal Review Board and the Ethical Review Committee at the Ludwig&#x02010;Maximilians&#x02010;University (LMU) Hospital, Munich, Germany, approved the protocol of this research project (Protocol Nr. 23&#x02013;0128).</p></sec><sec sec-type="conclusions" id="cam470655-sec-0021"><title>Consent</title><p>Patient consent was waived for this analysis due to its retrospective design and irreversible anonymization of all data. All authors have read and agreed to the published version of the manuscript.</p></sec><sec sec-type="COI-statement" id="cam470655-sec-0022"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="cam470655-supitem-0001" position="float" content-type="local-data"><caption><p>
Data S1:
</p></caption><media xlink:href="CAM4-14-e70655-s001.docx"/></supplementary-material></sec></body><back><ack id="cam470655-sec-0019"><title>Acknowledgments</title><p>This study received no external funding. Open Access funding enabled and organized by Projekt DEAL.</p></ack><sec sec-type="data-availability" id="cam470655-sec-0024"><title>Data Availability Statement</title><p>The data presented in this study are available on specific request from the corresponding author. The data are not publicly available for reasons of data protection and data economy.</p></sec><ref-list content-type="cited-references" id="cam470655-bibl-0001"><title>References</title><ref id="cam470655-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="cam470655-cit-0001">
<string-name>
<given-names>R. L.</given-names>
<surname>Siegel</surname>
</string-name>, <string-name>
<given-names>K. D.</given-names>
<surname>Miller</surname>
</string-name>, and <string-name>
<given-names>A.</given-names>
<surname>Jemal</surname>
</string-name>, &#x0201c;<article-title>Cancer Statistics, 2020</article-title>,&#x0201d; <source>CA: A Cancer Journal for Clinicians</source>
<volume>70</volume>, no. <issue>1</issue> (<year>2020</year>): <fpage>7</fpage>&#x02013;<lpage>30</lpage>, <pub-id pub-id-type="doi">10.3322/caac.21590</pub-id>.<pub-id pub-id-type="pmid">31912902</pub-id>
</mixed-citation></ref><ref id="cam470655-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="cam470655-cit-0002">
<string-name>
<given-names>S.</given-names>
<surname>George</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Serrano</surname>
</string-name>, <string-name>
<given-names>M. L.</given-names>
<surname>Hensley</surname>
</string-name>, and <string-name>
<given-names>I.</given-names>
<surname>Ray&#x02010;Coquard</surname>
</string-name>, &#x0201c;<article-title>Soft Tissue and Uterine Leiomyosarcoma</article-title>,&#x0201d; <source>Journal of Clinical Oncology</source>
<volume>36</volume> (<year>2018</year>): <fpage>144</fpage>&#x02013;<lpage>150</lpage>, <pub-id pub-id-type="doi">10.1200/JCO.2017.75.9845</pub-id>.<pub-id pub-id-type="pmid">29220301</pub-id>
</mixed-citation></ref><ref id="cam470655-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="cam470655-cit-0003">
<string-name>
<given-names>E.</given-names>
<surname>D'Angelo</surname>
</string-name> and <string-name>
<given-names>J.</given-names>
<surname>Prat</surname>
</string-name>, &#x0201c;<article-title>Uterine Sarcomas: A Review</article-title>,&#x0201d; <source>Gynecologic Oncology</source>
<volume>116</volume> (<year>2010</year>): <fpage>131</fpage>&#x02013;<lpage>139</lpage>, <pub-id pub-id-type="doi">10.1016/j.ygyno.2009.09.023</pub-id>.<pub-id pub-id-type="pmid">19853898</pub-id>
</mixed-citation></ref><ref id="cam470655-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="cam470655-cit-0004">
<string-name>
<given-names>R. A.</given-names>
<surname>Gladdy</surname>
</string-name>, <string-name>
<given-names>L. X.</given-names>
<surname>Qin</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Moraco</surname>
</string-name>, <string-name>
<given-names>N. P.</given-names>
<surname>Agaram</surname>
</string-name>, <string-name>
<given-names>M. F.</given-names>
<surname>Brennan</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Singer</surname>
</string-name>, &#x0201c;<article-title>Predictors of Survival and Recurrence in Primary Leiomyosarcoma</article-title>,&#x0201d; <source>Annals of Surgical Oncology</source>
<volume>20</volume> (<year>2013</year>): <fpage>1851</fpage>&#x02013;<lpage>1857</lpage>, <pub-id pub-id-type="doi">10.1245/s10434-013-2876-y</pub-id>.<pub-id pub-id-type="pmid">23354568</pub-id>
</mixed-citation></ref><ref id="cam470655-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="cam470655-cit-0005">
<string-name>
<given-names>F. J.</given-names>
<surname>Major</surname>
</string-name>, <string-name>
<given-names>J. A.</given-names>
<surname>Blessing</surname>
</string-name>, <string-name>
<given-names>S. G.</given-names>
<surname>Silverberg</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Prognostic Factors in Early&#x02010;Stage Uterine Sarcoma: A Gynecologic Oncology Group Study</article-title>,&#x0201d; <source>Cancer</source>
<volume>71</volume> (<year>1993</year>): <fpage>1702</fpage>&#x02013;<lpage>1709</lpage>, <pub-id pub-id-type="doi">10.1002/cncr.2820710440</pub-id>.<pub-id pub-id-type="pmid">8381710</pub-id>
</mixed-citation></ref><ref id="cam470655-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="cam470655-cit-0006">
<string-name>
<given-names>A.</given-names>
<surname>Gronchi</surname>
</string-name>, <string-name>
<given-names>A. B.</given-names>
<surname>Miah</surname>
</string-name>, <string-name>
<given-names>A. P.</given-names>
<surname>Dei Tos</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Soft Tissue and Visceral Sarcomas: ESMO&#x02013;EURACAN&#x02013;GENTURIS Clinical Practice Guidelines for Diagnosis, Treatment and Follow&#x02010;Up&#x02606;</article-title>,&#x0201d; <source>Annals of Oncology</source>
<volume>32</volume> (<year>2021</year>): <fpage>1348</fpage>&#x02013;<lpage>1365</lpage>, <pub-id pub-id-type="doi">10.1016/j.annonc.2021.07.006</pub-id>.<pub-id pub-id-type="pmid">34303806</pub-id>
</mixed-citation></ref><ref id="cam470655-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="cam470655-cit-0007">
<string-name>
<given-names>S.</given-names>
<surname>Pasquali</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Palmerini</surname>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>Quagliuolo</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Neoadjuvant Chemotherapy in High&#x02010;Risk Soft Tissue Sarcomas: A Sarculator&#x02010;Based Risk Stratification Analysis of the ISG&#x02010;STS 1001 Randomized Trial</article-title>,&#x0201d; <source>Cancer (Philadelphia, Pa.)</source>
<volume>128</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>85</fpage>&#x02013;<lpage>93</lpage>, <pub-id pub-id-type="doi">10.1002/cncr.33895</pub-id>.<pub-id pub-id-type="pmid">34643947</pub-id>
</mixed-citation></ref><ref id="cam470655-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="cam470655-cit-0008">
<string-name>
<given-names>L.</given-names>
<surname>D'Ambrosio</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Touati</surname>
</string-name>, <string-name>
<given-names>J. Y.</given-names>
<surname>Blay</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Doxorubicin Plus Dacarbazine, Doxorubicin Plus Ifosfamide, or Doxorubicin Alone as a First&#x02010;Line Treatment for Advanced Leiomyosarcoma: A Propensity Score Matching Analysis From the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group</article-title>,&#x0201d; <source>Cancer (Philadelphia, Pa.)</source>
<volume>126</volume>, no. <issue>11</issue> (<year>2020</year>): <fpage>2637</fpage>&#x02013;<lpage>2647</lpage>, <pub-id pub-id-type="doi">10.1002/cncr.32795</pub-id>.<pub-id pub-id-type="pmid">32129883</pub-id>
</mixed-citation></ref><ref id="cam470655-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="cam470655-cit-0009">
<string-name>
<given-names>S.</given-names>
<surname>Sleijfer</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Ouali</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Van Glabbeke</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Prognostic and Predictive Factors for Outcome to First&#x02010;Line Ifosfamide&#x02010;Containing Therapy (IFM) in Patients (Pts) With Advanced Soft Tissue Sarcomas (STS) Treated in EORTC&#x02010;STBSG Studies</article-title>,&#x0201d; <source>Journal of Clinical Oncology</source>
<volume>26</volume> (<year>2008</year>): <elocation-id>10509</elocation-id>, <pub-id pub-id-type="doi">10.1200/jco.2008.26.15_suppl.10509</pub-id>.</mixed-citation></ref><ref id="cam470655-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="cam470655-cit-0010">
<string-name>
<given-names>G. A.</given-names>
<surname>Omura</surname>
</string-name>, <string-name>
<given-names>F. J.</given-names>
<surname>Major</surname>
</string-name>, <string-name>
<given-names>J. A.</given-names>
<surname>Blessing</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>A Randomized Study of Adriamycin With and Without Dimethyl Triazenoimidazole Carboxamide in Advanced Uterine Sarcomas</article-title>,&#x0201d; <source>Cancer</source>
<volume>52</volume> (<year>1983</year>): <fpage>626</fpage>&#x02013;<lpage>632</lpage>, <pub-id pub-id-type="doi">10.1002/1097-0142(19830815)52:4&#x0003c;626::AID-CNCR2820520409&#x0003e;3.0.CO;2-E</pub-id>.<pub-id pub-id-type="pmid">6344983</pub-id>
</mixed-citation></ref><ref id="cam470655-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="cam470655-cit-0011">
<string-name>
<given-names>U.</given-names>
<surname>Bitz</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Pink</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Busemann</surname>
</string-name>, and <string-name>
<given-names>P.</given-names>
<surname>Reichardt</surname>
</string-name>, &#x0201c;<article-title>Doxorubicin (Doxo) and Dacarbacin (DTIC) as First&#x02010;Line Therapy for Patients (Pts) With Locally Advanced or Metastatic Leiomyosarcoma (LMS) and Liposarcoma (LPS)</article-title>,&#x0201d; <source>Journal of Clinical Oncology</source>
<volume>29</volume> (<year>2011</year>): <elocation-id>10094</elocation-id>, <pub-id pub-id-type="doi">10.1200/jco.2011.29.15_suppl.10094</pub-id>.</mixed-citation></ref><ref id="cam470655-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="cam470655-cit-0012">
<string-name>
<given-names>M.</given-names>
<surname>Zalupski</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Metch</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Balcerzak</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Phase III Comparison of Doxorubicin and Dacarbazine Given by Bolus Versus Infusion in Patients with Soft&#x02010;Tissue Sarcomas: A Southwest Oncology Group Study</article-title>,&#x0201d; <source>Journal of the National Cancer Institute</source>
<volume>83</volume> (<year>1991</year>): <fpage>926</fpage>&#x02013;<lpage>932</lpage>, <pub-id pub-id-type="doi">10.1093/jnci/83.13.926</pub-id>.<pub-id pub-id-type="pmid">2067035</pub-id>
</mixed-citation></ref><ref id="cam470655-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="cam470655-cit-0013">
<string-name>
<given-names>J. H.</given-names>
<surname>Saiki</surname>
</string-name>, <string-name>
<given-names>L. H.</given-names>
<surname>Baker</surname>
</string-name>, <string-name>
<given-names>S. E.</given-names>
<surname>Rivkin</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>A Useful High&#x02010;Dose Intermittent Schedule of Adriamycin and DTIC in the Treatment of Advanced Sarcomas</article-title>,&#x0201d; <source>Cancer</source>
<volume>58</volume> (<year>1986</year>): <fpage>2196</fpage>&#x02013;<lpage>2197</lpage>, <pub-id pub-id-type="doi">10.1002/1097-0142(19861115)58:10&#x0003c;2196::AID-CNCR2820581005&#x0003e;3.0.CO;2-J</pub-id>.<pub-id pub-id-type="pmid">3756766</pub-id>
</mixed-citation></ref><ref id="cam470655-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="cam470655-cit-0014">
<string-name>
<given-names>P.</given-names>
<surname>Pautier</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Italiano</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Piperno&#x02010;Neumann</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Doxorubicin Alone Versus Doxorubicin With Trabectedin Followed by Trabectedin Alone as First&#x02010;Line Therapy for Metastatic or Unresectable Leiomyosarcoma (LMS&#x02010;04): A Randomised, Multicentre, Open&#x02010;Label Phase 3 Trial</article-title>,&#x0201d; <source>Lancet Oncology</source>
<volume>23</volume>, no. <issue>8</issue> (<year>2022</year>): <fpage>1044</fpage>&#x02013;<lpage>1054</lpage>, <pub-id pub-id-type="doi">10.1016/S1470-2045(22)00380-1</pub-id>.<pub-id pub-id-type="pmid">35835135</pub-id>
</mixed-citation></ref><ref id="cam470655-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="cam470655-cit-0015">
<string-name>
<given-names>P.</given-names>
<surname>Pautier</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Italiano</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Piperno&#x02010;Neumann</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Doxorubicin&#x02010;Trabectedin With Trabectedin Maintenance in Leiomyosarcoma</article-title>,&#x0201d; <source>New England Journal of Medicine</source>
<volume>391</volume>, no. <issue>9</issue> (<year>2024</year>): <fpage>789</fpage>&#x02013;<lpage>799</lpage>, <pub-id pub-id-type="doi">10.1056/NEJMoa2403394</pub-id>.<pub-id pub-id-type="pmid">39231341</pub-id>
</mixed-citation></ref><ref id="cam470655-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="cam470655-cit-0016">
<string-name>
<given-names>I.</given-names>
<surname>Judson</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Verweij</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Gelderblom</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Doxorubicin Alone Versus Intensified Doxorubicin Plus Ifosfamide for First&#x02010;Line Treatment of Advanced or Metastatic Soft&#x02010;Tissue Sarcoma: A Randomised Controlled Phase 3 Trial</article-title>,&#x0201d; <source>Lancet Oncology</source>
<volume>15</volume> (<year>2014</year>): <fpage>415</fpage>&#x02013;<lpage>423</lpage>, <pub-id pub-id-type="doi">10.1016/S1470-2045(14)70063-4</pub-id>.<pub-id pub-id-type="pmid">24618336</pub-id>
</mixed-citation></ref><ref id="cam470655-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="cam470655-cit-0017">
<string-name>
<given-names>M.</given-names>
<surname>Von Mehren</surname>
</string-name>, <string-name>
<given-names>R. L.</given-names>
<surname>Randall</surname>
</string-name>, <string-name>
<given-names>R. S.</given-names>
<surname>Benjamin</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology</article-title>,&#x0201d; <source>Journal of the National Comprehensive Cancer Network</source>
<volume>16</volume>, no. <issue>5</issue> (<year>2018</year>): <fpage>536</fpage>&#x02013;<lpage>563</lpage>, <pub-id pub-id-type="doi">10.6004/jnccn.2018.0025</pub-id>.<pub-id pub-id-type="pmid">29752328</pub-id>
</mixed-citation></ref><ref id="cam470655-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="cam470655-cit-0018">
<string-name>
<given-names>A.</given-names>
<surname>Gronchi</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Ferrari</surname>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>Quagliuolo</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Histotype&#x02010;Tailored Neoadjuvant Chemotherapy Versus Standard Chemotherapy in Patients With High&#x02010;Risk Soft&#x02010;Tissue Sarcomas (ISG&#x02010;STS 1001): An International, Open&#x02010;Label, Randomised, Controlled, Phase 3, Multicentre Trial</article-title>,&#x0201d; <source>Lancet Oncology</source>
<volume>18</volume>, no. <issue>6</issue> (<year>2017</year>): <fpage>812</fpage>&#x02013;<lpage>822</lpage>, <pub-id pub-id-type="doi">10.1016/S1470-2045(17)30334-0</pub-id>.<pub-id pub-id-type="pmid">28499583</pub-id>
</mixed-citation></ref><ref id="cam470655-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="cam470655-cit-0019">
<string-name>
<given-names>B.</given-names>
<surname>Seddon</surname>
</string-name>, <string-name>
<given-names>S. J.</given-names>
<surname>Strauss</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Whelan</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Gemcitabine and Docetaxel Versus Doxorubicin as First&#x02010;Line Treatment in Previously Untreated Advanced Unresectable or Metastatic Soft&#x02010;Tissue Sarcomas (GeDDiS): A Randomised Controlled Phase 3 Trial</article-title>,&#x0201d; <source>Lancet Oncology</source>
<volume>18</volume>, no. <issue>10</issue> (<year>2017</year>): <fpage>1397</fpage>&#x02013;<lpage>1410</lpage>, <pub-id pub-id-type="doi">10.1016/S1470-2045(17)30622-8</pub-id>.<pub-id pub-id-type="pmid">28882536</pub-id>
</mixed-citation></ref><ref id="cam470655-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="cam470655-cit-0020">
<string-name>
<given-names>R. D.</given-names>
<surname>Issels</surname>
</string-name>, <string-name>
<given-names>L. H.</given-names>
<surname>Lindner</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Verweij</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long&#x02010;Term Outcomes Among Patients With Localized High&#x02010;Risk Soft Tissue Sarcoma</article-title>,&#x0201d; <source>JAMA Oncology</source>
<volume>4</volume>, no. <issue>4</issue> (<year>2018</year>): <fpage>483</fpage>, <pub-id pub-id-type="doi">10.1001/jamaoncol.2017.4996</pub-id>.<pub-id pub-id-type="pmid">29450452</pub-id>
</mixed-citation></ref><ref id="cam470655-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="cam470655-cit-0021">
<string-name>
<given-names>R. D.</given-names>
<surname>Issels</surname>
</string-name>, <string-name>
<given-names>L. H.</given-names>
<surname>Lindner</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Verweij</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Neo&#x02010;Adjuvant Chemotherapy Alone or With Regional Hyperthermia for Localised High&#x02010;Risk Soft&#x02010;Tissue Sarcoma: A Randomised Phase 3 Multicentre Study</article-title>,&#x0201d; <source>Lancet Oncology</source>
<volume>11</volume>, no. <issue>6</issue> (<year>2010</year>): <fpage>p561</fpage>&#x02013;<lpage>p570</lpage>, <pub-id pub-id-type="doi">10.1016/S1470-2045(10)70071-1</pub-id>.</mixed-citation></ref><ref id="cam470655-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="cam470655-cit-0022">
<string-name>
<given-names>R. D.</given-names>
<surname>Issels</surname>
</string-name>, &#x0201c;<article-title>Hyperthermia Adds to Chemotherapy</article-title>,&#x0201d; <source>European Journal of Cancer</source>
<volume>44</volume> (<year>2008</year>): <fpage>2546</fpage>&#x02013;<lpage>2554</lpage>, <pub-id pub-id-type="doi">10.1016/j.ejca.2008.07.038</pub-id>.<pub-id pub-id-type="pmid">18789678</pub-id>
</mixed-citation></ref><ref id="cam470655-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="cam470655-cit-0023">
<string-name>
<given-names>R.</given-names>
<surname>Issels</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Kampmann</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Kanaar</surname>
</string-name>, and <string-name>
<given-names>L. H.</given-names>
<surname>Lindner</surname>
</string-name>, &#x0201c;<article-title>Hallmarks of Hyperthermia in Driving the Future of Clinical Hyperthermia as Targeted Therapy: Translation Into Clinical Application</article-title>,&#x0201d; <source>International Journal of Hyperthermia</source>
<volume>32</volume> (<year>2016</year>): <fpage>89</fpage>&#x02013;<lpage>95</lpage>, <pub-id pub-id-type="doi">10.3109/02656736.2015.1119317</pub-id>.<pub-id pub-id-type="pmid">26803991</pub-id>
</mixed-citation></ref><ref id="cam470655-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="cam470655-cit-0024">
<string-name>
<given-names>R. D.</given-names>
<surname>Issels</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Noessner</surname>
</string-name>, <string-name>
<given-names>L. H.</given-names>
<surname>Lindner</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Immune Infiltrates in Patients With Localised High&#x02010;Risk Soft Tissue Sarcoma Treated With Neoadjuvant Chemotherapy Without or With Regional Hyperthermia: A Translational Research Program of the EORTC 62961&#x02010;ESHO 95 Randomised Clinical Trial</article-title>,&#x0201d; <source>European Journal of Cancer</source>
<volume>158</volume> (<year>2021</year>): <fpage>123</fpage>&#x02013;<lpage>132</lpage>, <pub-id pub-id-type="doi">10.1016/j.ejca.2021.09.015</pub-id>.<pub-id pub-id-type="pmid">34666214</pub-id>
</mixed-citation></ref><ref id="cam470655-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="cam470655-cit-0025">
<string-name>
<given-names>G.</given-names>
<surname>Wiedemann</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Roszinski</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Biersack</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Weiss</surname>
</string-name>, and <string-name>
<given-names>T.</given-names>
<surname>Wagner</surname>
</string-name>, &#x0201c;<article-title>Local Hyperthermia Enhances Cyclophosphamide, Ifosfamide and <italic toggle="yes">cis</italic>&#x02010;Diamminedichloroplatinum Cytotoxicity on Human&#x02010;Derived Breast Carcinoma and Sarcoma Xenografts in Nude Mice</article-title>,&#x0201d; <source>Journal of Cancer Research and Clinical Oncology</source>
<volume>118</volume>, no. <issue>2</issue> (<year>1992</year>): <fpage>129</fpage>&#x02013;<lpage>135</lpage>, <pub-id pub-id-type="doi">10.1007/BF01187501</pub-id>.<pub-id pub-id-type="pmid">1735733</pub-id>
</mixed-citation></ref><ref id="cam470655-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="cam470655-cit-0026">
<string-name>
<given-names>H. H.</given-names>
<surname>Kampinga</surname>
</string-name>, &#x0201c;<article-title>Cell Biological Effects of Hyperthermia Alone or Combined With Radiation or Drugs: A Short Introduction to Newcomers in the Field</article-title>,&#x0201d; <source>International Journal of Hyperthermia</source>
<volume>22</volume> (<year>2006</year>): <fpage>191</fpage>&#x02013;<lpage>196</lpage>, <pub-id pub-id-type="doi">10.1080/02656730500532028</pub-id>.<pub-id pub-id-type="pmid">16754338</pub-id>
</mixed-citation></ref><ref id="cam470655-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="cam470655-cit-0027">
<string-name>
<given-names>M.</given-names>
<surname>Urano</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Kuroda</surname>
</string-name>, and <string-name>
<given-names>Y.</given-names>
<surname>Nishimura</surname>
</string-name>, &#x0201c;<article-title>For the Clinical Application of Thermochemotherapy Given at Mild Temperatures</article-title>,&#x0201d; <source>International Journal of Hyperthermia</source>
<volume>15</volume> (<year>1999</year>): <fpage>79</fpage>&#x02013;<lpage>107</lpage>, <pub-id pub-id-type="doi">10.1080/026567399285765</pub-id>.<pub-id pub-id-type="pmid">10323618</pub-id>
</mixed-citation></ref><ref id="cam470655-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="cam470655-cit-0028">
<string-name>
<given-names>D.</given-names>
<surname>Salvador</surname>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>Bastos</surname>
</string-name>, and <string-name>
<given-names>H.</given-names>
<surname>Oliveira</surname>
</string-name>, &#x0201c;<article-title>Combined Therapy With Dacarbazine and Hyperthermia Induces Cytotoxicity in A375 and MNT&#x02010;1 Melanoma Cells</article-title>,&#x0201d; <source>International Journal of Molecular Sciences</source>
<volume>23</volume>, no. <issue>7</issue> (<year>2022</year>): <elocation-id>3586</elocation-id>, <pub-id pub-id-type="doi">10.3390/ijms23073586</pub-id>.<pub-id pub-id-type="pmid">35408947</pub-id>
</mixed-citation></ref><ref id="cam470655-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="cam470655-cit-0029">
<string-name>
<given-names>T.</given-names>
<surname>Mantso</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Vasileiadis</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Anestopoulos</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Hyperthermia Induces Therapeutic Effectiveness and Potentiates Adjuvant Therapy With Non&#x02010;Targeted and Targeted Drugs in an In&#x000a0;Vitro Model of Human Malignant Melanoma</article-title>,&#x0201d; <source>Scientific Reports</source>
<volume>8</volume> (<year>2018</year>): <fpage>10724</fpage>, <pub-id pub-id-type="doi">10.1038/s41598-018-29018-0</pub-id>.<pub-id pub-id-type="pmid">30013176</pub-id>
</mixed-citation></ref><ref id="cam470655-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="cam470655-cit-0030">
<string-name>
<given-names>J. J. W.</given-names>
<surname>Lagendijk</surname>
</string-name>, <string-name>
<given-names>G. C.</given-names>
<surname>Van Rhoon</surname>
</string-name>, <string-name>
<given-names>S. N.</given-names>
<surname>Hornsleth</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>ESHO Quality Assurance Guidelines for Regional Hyperthermia</article-title>,&#x0201d; <source>International Journal of Hyperthermia</source>
<volume>14</volume> (<year>1998</year>): <fpage>125</fpage>&#x02013;<lpage>133</lpage>, <pub-id pub-id-type="doi">10.3109/02656739809018219</pub-id>.<pub-id pub-id-type="pmid">9589319</pub-id>
</mixed-citation></ref><ref id="cam470655-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="cam470655-cit-0031">
<string-name>
<given-names>E. A.</given-names>
<surname>Eisenhauer</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Therasse</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Bogaerts</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1)</article-title>,&#x0201d; <source>European Journal of Cancer</source>
<volume>45</volume> (<year>2009</year>): <fpage>228</fpage>&#x02013;<lpage>247</lpage>, <pub-id pub-id-type="doi">10.1016/j.ejca.2008.10.026</pub-id>.<pub-id pub-id-type="pmid">19097774</pub-id>
</mixed-citation></ref><ref id="cam470655-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="cam470655-cit-0032">
<string-name>
<given-names>B. B.</given-names>
<surname>Hansen</surname>
</string-name> and <string-name>
<given-names>S. O.</given-names>
<surname>Klopfer</surname>
</string-name>, &#x0201c;<article-title>Optimal Full Matching and Related Designs via Network Flows</article-title>,&#x0201d; <source>Journal of Computational and Graphical Statistics</source>
<volume>15</volume>, no. <issue>3</issue> (<year>2006</year>): <fpage>609</fpage>&#x02013;<lpage>627</lpage>, <pub-id pub-id-type="doi">10.1198/106186006X137047</pub-id>.</mixed-citation></ref><ref id="cam470655-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="cam470655-cit-0033">
<string-name>
<given-names>S.</given-names>
<surname>Sleijfer</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Ouali</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>van Glabbeke</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Prognostic and Predictive Factors for Outcome to First&#x02010;Line Ifosfamide&#x02010;Containing Chemotherapy for Adult Patients With Advanced Soft Tissue Sarcomas</article-title>,&#x0201d; <source>European Journal of Cancer</source>
<volume>46</volume> (<year>2010</year>): <fpage>72</fpage>&#x02013;<lpage>83</lpage>, <pub-id pub-id-type="doi">10.1016/j.ejca.2009.09.022</pub-id>.<pub-id pub-id-type="pmid">19853437</pub-id>
</mixed-citation></ref><ref id="cam470655-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="cam470655-cit-0034">
<string-name>
<given-names>A.</given-names>
<surname>Le Cesne</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Judson</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Crowther</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Randomized Phase III Study Comparing Conventional&#x02010;Dose Doxorubicin Plus Ifosfamide Versus High&#x02010;Dose Doxorubicin Plus Infosfamide Plus Recombinant Human Granulocyte&#x02010;Macrophage Colony&#x02010;Stimulating Factor in Advanced Soft Tissue Sarcomas: A Trial of the Euro</article-title>,&#x0201d; <source>Journal of Clinical Oncology</source>
<volume>18</volume> (<year>2000</year>): <fpage>2676</fpage>&#x02013;<lpage>2684</lpage>, <pub-id pub-id-type="doi">10.1200/JCO.2000.18.14.2676</pub-id>.<pub-id pub-id-type="pmid">10894866</pub-id>
</mixed-citation></ref><ref id="cam470655-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="cam470655-cit-0035">
<string-name>
<given-names>M.</given-names>
<surname>Dunne</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Regenold</surname>
</string-name>, and <string-name>
<given-names>C.</given-names>
<surname>Allen</surname>
</string-name>, &#x0201c;<article-title>Hyperthermia Can Alter Tumor Physiology and Improve Chemo&#x02010; and Radio&#x02010;Therapy Efficacy</article-title>,&#x0201d; <source>Advanced Drug Delivery Reviews</source>
<volume>163&#x02013;164</volume> (<year>2020</year>): <fpage>98</fpage>&#x02013;<lpage>124</lpage>, <pub-id pub-id-type="doi">10.1016/j.addr.2020.07.007</pub-id>.</mixed-citation></ref><ref id="cam470655-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="cam470655-cit-0036">
<string-name>
<given-names>A.</given-names>
<surname>Gronchi</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Frustaci</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Mercuri</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Short, Full&#x02010;Dose Adjuvant Chemotherapy in High&#x02010;Risk Adult Soft Tissue Sarcomas: A Randomized Clinical Trial From the Italian Sarcoma Group and the Spanish Sarcoma Group</article-title>,&#x0201d; <source>Journal of Clinical Oncology</source>
<volume>30</volume> (<year>2012</year>): <fpage>850</fpage>&#x02013;<lpage>856</lpage>, <pub-id pub-id-type="doi">10.1200/JCO.2011.37.7218</pub-id>.<pub-id pub-id-type="pmid">22312103</pub-id>
</mixed-citation></ref><ref id="cam470655-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="cam470655-cit-0037">
<string-name>
<given-names>A.</given-names>
<surname>Gronchi</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Stacchiotti</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Verderio</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Short, Full&#x02010;Dose Adjuvant Chemotherapy (CT) in High&#x02010;Risk Adult Soft Tissue Sarcomas (STS): Long&#x02010;Term Follow&#x02010;Up of a Randomized Clinical Trial From the Italian Sarcoma Group and the Spanish Sarcoma Group</article-title>,&#x0201d; <source>Annals of Oncology</source>
<volume>27</volume> (<year>2016</year>): <fpage>2283</fpage>&#x02013;<lpage>2288</lpage>, <pub-id pub-id-type="doi">10.1093/annonc/mdw430</pub-id>.<pub-id pub-id-type="pmid">27733375</pub-id>
</mixed-citation></ref></ref-list></back></article>